177-lutetium-PSMA or Peptide Receptor Treatments

177-lutetium-PSMA in the treatment of metastatic prostate cancer

In January 2017, we were the first health care provider in Finland to use 177-lutetium-PSMA isotope therapy in the treatment of  advanced prostate cancer, which enables destroying metastases outside the bones efficiently without any severe adverse effects.

Before the treatment, we carry out a diagnostic PET scan using F-PSMA tracers to ensure that 177-lutetium-PSMA uptake occurs in the metastases.

177-lutetium-PSMA therapies are administered intravenously, and its their most common side effect is a dry mouth. Depending on the individual, the treatment is typically performed 2–6 times approximately every 4–6 weeks (177-lutetium-PSMA).

The multidisciplinary team in charge of peptide-receptor therapies at Docrates Cancer Center is led by Chief Physician in Nuclear Medicine Jukka Kemppainen.

The VISION study results* were presented in ESMO2021 conference: the results showed that treatment with 177-lutetium-PSMA significantly improved overall survival (OS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.

*Publiced in NEJM September 2021